Trial Information

Summary: A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Status: Completed

Protocol Number: HBV05

Sponsor:

Company Division: Diagnostic

Official Scientific Title: Peginterferon alfa-2a and ribavirin combination therapy in patients with HBeAg-negative chronic HBV infection (PARC Study)

Brief Summary: This study will investigate whether 48 weeks of combination therapy with PEGASYS and ribavirin enhances the virological and biochemical response, compared to PEGASYS monotherapy, in HbeAg-negative chronic hepatitis B patients.

Study Phase: N/A

Study Design / Study Details:

• Purpose:
• Allocation: Randomized
• Masking:
• Control:
• Assignment: Parallel
• Endpoints:

Study Type:

Condition: Hepatitis B, Chronic

Intervention Type: Diagnostic Test

Intervention Name: cobas TaqMan 48 HBV test

Primary Outcome:

Key Secondary Outcomes:

Inclusion Criteria:

Exclusion Criteria:

Gender: Males or Females

Age Limits: Min: 18 Years Max: 70 Years

Accepts Healthy Volunteers: No

Anticipated Start Date: March, 2005

Trial Registration Date: 03/16/2006

Date Last Updated: 02/07/2008

Link To Trial Results

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: August 20, 2008 at 2:16:32 PM